Content Conference Coverage Conferences IAS 2009
IAS 2009: ARIES Trial Shows Unboosted Atazanavir (Reyataz) Maintains Viral Suppression as well as Boosted Drug
- Details
- Category: HIV Treatment
- Created on Friday, 14 August 2009 13:49
The protease inhibitor atazanavir (Reyataz), taken with abacavir/lamivudine (Epzicom coformulation), was as likely to keep viral load undetectable after initial suppression as the same combination plus a boosting dose of ritonavir, researchers reported at the 5th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention (IAS 2009) last month in Cape Town, South Africa. The unboosted regimen, however, was less likely to cause cholesterol and triglyceride elevations.
IAS 2009: Can People in Low-income Countries Benefit from Antiretroviral Therapy without Routine Laboratory Monitoring?
- Details
- Category: HIV Treatment
- Created on Friday, 31 July 2009 13:49
Antiretroviral therapy (ART) should not be withheld from HIV patients in medium- and low-income countries due to lack of laboratory monitoring, according to results of the Development of Antiretroviral Therapy (DART) in Africa trial, presented last week at the 5th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention (IAS 2009) in Cape Town, South Africa. The researchers also concluded that first-line treatment regimens can be given to people in resource-limited countries without the need for routine laboratory monitoring of toxicity.
IAS 2009: Tenofovir/emtricitabine (Truvada) plus Lopinavir/ritonavir (Kaletra) or Raltegravir (Isentress) Work Well for Post-exposure Prophylaxis
- Details
- Category: HIV Prevention
- Created on Friday, 11 September 2009 13:49
Post-exposure prophylaxis (PEP) regimens consisting of tenofovir/emtricitabine (Truvada) plus lopinavir/ritonavir (Kaletra) or raltegravir (Isentress) prevent HIV infection as well as zidovudine/lamivudine (Combivir) regimens, but with fewer side effects, according to 2 presentations at the recent 5th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention (IAS 2009) in Cape Town, South Africa.
IAS 2009: At Opening of International AIDS Conference in South Africa, Scientists Warn against Cutting Back Funding for AIDS Programs
- Details
- Category: HIV Treatment
- Created on Tuesday, 21 July 2009 13:49
As more than 5,000 researchers, people with HIV/AIS and HIV community advocates gathered in Cape Town, South Africa for the 5th IAS Conference on HIV Pathogenesis, Treatment an AIDS (IAS 2009), July 19 - 22, 2009, speakers at the open ceremonies warned against a loss of momentum in the global fight against the HIV pandemic. There is heightened concern that due to the global recession, governments and other donors are scaling back on their financial support for healthcare delivery systems.
IAS 2009: Vitamin D Deficiency is Common among HIV Positive People and Is Associated with NNRTI Use, Black Race, and Smoking
- Details
- Category: HIV-Related Conditions
- Created on Tuesday, 01 September 2009 13:49
Two research teams presented study findings at the recent 5th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention (IAS 2009) in Cape Town, South Africa, showing that inadequate vitamin D levels are highly prevalent among people with HIV, and individuals taking efavirenz (Sustiva) are at particularly high risk
Web Design and Development by